Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | HTR1A | P08908 | 6/20 | 0.53 |
| ▸ | HTR7 | P34969 | 6/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28097371 | 0.91 | MAPT (0.54) | SLC6A4OPRM1OPRK1MAPTLMNA | |
| SCHEMBL16801734 | 0.89 | SLC6A4 (0.69) | SLC6A4OPRM1OPRK1MAPTDRD2 | |
| SCHEMBL3233304 | 0.86 | SLC6A4 (0.67) | SLC6A4MAPTDRD2HTR1AHTR7 | |
| SCHEMBL1232327 | 0.86 | SLC6A4 (0.50) | SLC6A4MAPT | |
| SCHEMBL9462544 | 0.85 | SLC6A4 (0.65) | SLC6A4OPRM1OPRK1MAPTDRD2 | |
| SCHEMBL892861 | 0.84 | GABRP (0.62) | SLC6A4OPRM1OPRK1MAPTDRD2 | |
| SCHEMBL30567971 | 0.84 | GABRP (0.62) | SLC6A4OPRM1OPRK1MAPTDRD2 | |
| SCHEMBL6345407 | 0.83 | SLC6A4 (0.69) | SLC6A4HTR1AHTR6 | |
| SCHEMBL4178633 | 0.83 | SLC6A4 (0.70) | SLC6A4MAPTDRD2HTR1AHTR6 | |
| SCHEMBL28097296 | 0.83 | LMNA (0.64) | SLC6A4MAPTDRD2HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-106045966-B | Substituted heterocyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-106045967-B | Substituted heterocyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
| CN-106045966-A | Substituted heterocyclic compounds and application of same to medicines | 广东东阳光药业有限公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-106045967-A | Substituted heterocyclic compounds and application of same to medicines | 广东东阳光药业有限公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-2440550-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
| CN-101541765-A | 3-piperidin-4-yl-indole ORL-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-23 | — | — | CN | disclosed |